Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
Nagy S, Hafner P, Schmidt S, Rubino-Nacht D, Schädelin S, Bieri O, Fischer D.
Trials. 2019. 20(1), 637.
Protocol of a multicenter, randomized, double-blind, placebo-controlled phase III trial study aiming to demonstrate safety and efficacy of tamoxifen over placebo in pediatric patients with DMD.
Keywords: 6-min walk test; Duchenne muscular dystrophy; Motor function measure; Quantitative muscle MRI; Randomized placebo-controlled trial; Tamoxifen
Articles in scientific journals
Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study
Figueroa-Bonaparte S, Llauger J, Segovia S, Belmonte I, Pedrosa I, Montiel E, Montesinos P, Sánchez-González J, Alonso-Jiménez A, Gallardo E, Illa I, Díaz-Manera J ; Spanish Pompe group.Sci Rep. 2018. 18;8(1):10898. In this study, 32 Late onset Pompe disease patients...
Turkish version of the Motor Function Measure Scale (MFM-32) forneuromuscular diseases: a cross-cultural adaptation, reliability, and validity study
Inal HS, Tarakçi E, Tarakçi D, Aksoy G, Mergen Kiliç S, Beser H, Beser Ç, Özdinçler AR, Durmus Tekçe H, Parman FY, Deymeer F, Oflazer ZP Turk J Med Sci. 2017. 19;47(6):1826-1833. Study aiming to analyze the reliability and validity of a translation and cultural...
Long term longitudinal study of muscle function in patients with glycogen storage disease type IIIa
Decostre V, Laforêt P, De Antonio M, Kachetel K, Canal A, Ollivier G, Nadaj-Pakleza A, Petit FM, Wahbi K, Fayssoil A, Eymard B, Behin A, Labrune P, Hogrel JY Mol Genet Metab. 2017. 122(3):108-116. Preliminary results of a longitudinal study assessing in patients with...
Adding quantitative muscle MRI to the FSHD clinical trial toolbox
Mul K, Vincenten SCC, Voermans NC, Lemmers RJLF, van der Vliet PJ, van der Maarel SM, Padberg GW, Horlings CGC, van Engelen BGM Neurology. 2017. 14;89(20):2057-2065. Assessment from a cohort of 140 patients with facioscapulohumeral muscular dystrophy (FSHD) of...
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial
Bertini E, Dessaud E, Mercuri E, Muntoni F, Kirschner J, Reid C, Lusakowska A, Comi GP, Cuisset JM, Abitbol JL, Scherrer B, Ducray PS, Buchbjerg J, Vianna E, van der Pol WL, Vuillerot C, Blaettler T, Fontoura P; Olesoxime SMA Phase 2 Study Investigators Lancet Neurol....
Improvements in motor tasks through the use of smartphone technology for individuals with Duchenne muscular dystrophy
Capelini CM, da Silva TD, Tonks J, Watson S, Alvarez MPB, de Menezes LDC, Favero FM, Caromano FA, Massetti T, de Mello Monteiro CB Neuropsychiatr Dis Treat. 2017. 18(13):2209-2217. The main aim of the study was to verify whether individuals with Duchenne muscular...